NCT03250663View on ClinicalTrials.gov

Eucrisa for Atopic Dermatitis

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 1, 2017

Primary Completion Date

July 27, 2022

Study Completion Date

July 27, 2022

Conditions
Mild to Moderate Atopic Dermatitis
Interventions
BEHAVIORAL

Online Treatment response

Electronic treatment response survey to track use of study medication, EUCRISA (crisaborole) ointment 2%.

DRUG

EUCRISA

Participants are given EUCRISA (crisaborole) ointment 2%.

Trial Locations (1)

27157

Wake Forest University Heath Sciences, Winston-Salem

All Listed Sponsors
lead

Wake Forest University Health Sciences

OTHER

NCT03250663 - Eucrisa for Atopic Dermatitis | Biotech Hunter | Biotech Hunter